Starting Point of Virginia, P.C.
Starting Point of Virginia, P.C. was paid $28.98M by Medicaid between Dec 2018 and Dec 2024, across 29 billing codes. Its largest line is G9012, Other specified case management service not elsewhere classified — 27% of everything it billed.
ABINGDON, VA 24210
Next to other Addiction Medicine (Psychiatry & Neurology) Physician providers in Virginia
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Paid by month
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 40 | $0.00 | |
| 2019 | 16,635 | $397K | |
| 2020 | 33,978 | $2.40M | |
| 2021 | 92,331 | $6.90M | |
| 2022 | 75,843 | $6.00M | |
| 2023 | 96,052 | $6.54M | |
| 2024incomplete | 93,569 | $6.73M |
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| G9012 | Other specified case management service not elsewhere classified | 27% | 39,528 | 36,062 | $7.95M |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 18% | 95,724 | 55,784 | $5.23M |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | 14% | 40,553 | 18,348 | $4.04M |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 9.7% | 20,184 | 11,998 | $2.81M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 8.6% | 49,334 | 36,671 | $2.49M |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 8.2% | 34,796 | 30,014 | $2.38M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 6.3% | 27,753 | 18,273 | $1.83M |
| H0004 | Behavioral health counseling and therapy, per 15 minutes | 3.4% | 46,262 | 32,909 | $988K |
| 99215 | Doctor's office visit, returning patient (complex)Prolong outpt/office vis | 1.6% | 6,515 | 3,213 | $465K |
| 80305 | 1.1% | 28,996 | 21,134 | $314K | |
| H0014 | Alcohol and/or drug services; ambulatory detoxification | <1% | 1,790 | 1,676 | $211K |
| 90791 | Psychiatric diagnostic evaluationPsychiatric diagnostic evaluation | <1% | 848 | 805 | $93K |
17 more codes
| 99408 | <1% | 2,830 | $60K | |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 851 | $24K |
| 99406 | <1% | 3,824 | $23K | |
| H0020 | Alcohol and/or drug services; methadone administration and/or service (provision of the drug by a licensed program) | <1% | 3,012 | $23K |
| S0109 | Methadone, oral, 5 mg | <1% | 4,341 | $17K |
| 90833 | Psychotherapy, 30 minutes with patient when performed with an E&M service (add-on) | <1% | 254 | $16K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | <1% | 59 | $7K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 37 | $3K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 127 | $2K |
| 82075 | <1% | 415 | $1K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 12 | $966.01 |
| 81025 | <1% | 170 | $941.70 | |
| 99484 | <1% | 62 | $470.01 | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 44 | $463.48 |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 18 | $442.78 |
| H0005 | Alcohol and/or drug services; group counseling by a clinician | <1% | 93 | $406.00 |
| H0047 | Alcohol and/or other drug abuse services, not otherwise specified | 0% | 16 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
Who's on the registration
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.